RCKT ROCKET PHARMACEUTICALS, INC.

Nasdaq rocketpharma.com


$ 3.17 $ -0.13 (-3.94 %)    

Thursday, 13-Nov-2025 15:59:55 EST
QQQ $ 608.59 $ -9.26 (-1.5 %)
DIA $ 475.50 $ -6.59 (-1.37 %)
SPY $ 672.57 $ -8.41 (-1.24 %)
TLT $ 89.38 $ -0.42 (-0.46 %)
GLD $ 384.40 $ -4.31 (-1.11 %)
$ 3.17
$ 3.23
$ 3.05 x 1,000
$ 3.31 x 25
-- - --
$ 2.19 - $ 15.95
1,545,574
na
343.06M
$ 1.42
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-08-2025 03-31-2025 10-Q
4 02-27-2025 01-01-1970 10-K
5 02-27-2025 12-31-2024 10-K
6 11-07-2024 09-30-2024 10-Q
7 08-06-2024 06-30-2024 10-Q
8 05-07-2024 03-31-2024 10-Q
9 02-27-2024 12-31-2023 10-K
10 11-07-2023 09-30-2023 10-Q
11 08-09-2023 06-30-2023 10-Q
12 05-05-2023 03-31-2023 10-Q
13 02-28-2023 12-31-2022 10-K
14 11-04-2022 09-30-2022 10-Q
15 08-09-2022 06-30-2022 10-Q
16 05-06-2022 03-31-2022 10-Q
17 02-28-2022 12-31-2021 10-K
18 11-05-2021 09-30-2021 10-Q
19 08-09-2021 06-30-2021 10-Q
20 05-10-2021 03-31-2021 10-Q
21 03-01-2021 12-31-2020 10-K
22 11-06-2020 09-30-2020 10-Q
23 08-05-2020 06-30-2020 10-Q
24 05-08-2020 03-31-2020 10-Q
25 03-06-2020 12-31-2019 10-K
26 11-08-2019 09-30-2019 10-Q
27 08-08-2019 06-30-2019 10-Q
28 05-09-2019 03-31-2019 10-Q
29 03-08-2019 12-31-2018 10-K
30 11-09-2018 09-30-2018 10-Q
31 08-14-2018 06-30-2018 10-Q
32 05-11-2018 03-31-2018 10-Q
33 03-07-2018 12-31-2017 10-K
34 11-08-2017 09-30-2017 10-Q
35 08-03-2017 06-30-2017 10-Q
36 05-10-2017 03-31-2017 10-Q
37 03-16-2017 12-31-2016 10-K
38 11-09-2016 09-30-2016 10-Q
39 08-10-2016 06-30-2016 10-Q
40 05-11-2016 03-31-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 fdas-rigid-approach-adds-uncertainty-to-uniqures-accelerated-pathway-for-huntingtons-gene-therapy

William Blair notes FDA's tougher stance on gene therapy programs as AMT-130 faces uncertainty in its accelerated approval ...

 fda-acceptance-of-rocket-pharmaceuticals-lead-gene-therapy-application-reestablishes-momentum-for-stock

FDA accepts Rocket Pharmaceuticals' resubmission for Kresladi gene therapy in severe LAD-I, with a decision expected by Mar...

 chardan-capital-maintains-buy-on-rocket-pharmaceuticals-maintains-11-price-target

Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $11 price ta...

 the-fda-has-accepted-the-resubmission-of-rocket-pharmaceuticals-marketing-application-for-kresladi-marnetegragene-autotemcel-marne-cel-an-investigational-gene-therapy-for-severe-leukocyte-adhesion-deficiency-i-pdufa-date-is-march-28-2026

Prescription Drug User Fee Act (PDUFA) target action date is March 28, 2026All primary and secondary endpoints were met, and KR...

 leerink-partners-maintains-market-perform-on-rocket-pharmaceuticals-lowers-price-target-to-7

Leerink Partners analyst Mani Foroohar maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Market Perform and lowers the p...

 fda-outlines-process-to-speed-up-rare-disease-therapy-approvals

FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questi...

 rocket-pharmaceuticals-cfo-aaron-ondrey-resigns-martin-wilson-appointed-interim-cfo-effective-september-8

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangemen...

 the-european-medicines-agency-just-disclosed-that-rocket-pharmaceuticals-has-withdrawn-its-application-for-marketing-authorization-of-fanskya-the-ema-concluded-that-the-benefit-of-mozafancogene-autotemcel-did-not-outweigh-its-risks---ema

https://www.ema.europa.eu/en/documents/medicine-qa/questions-answers-withdrawal-application-marketing-authorisation-fanskya-moz...

 b-of-a-securities-upgrades-rocket-pharmaceuticals-to-buy-raises-price-target-to-10

B of A Securities analyst Jason Zemansky upgrades Rocket Pharmaceuticals (NASDAQ:RCKT) from Neutral to Buy and raises the pr...

 chardan-capital-maintains-buy-on-rocket-pharmaceuticals-maintains-11-price-target

Chardan Capital analyst Geulah Livshits maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Buy and maintains $11 price ta...

 fda-lifts-rocket-pharmaceuticals-study-hold-for-rare-disease-gene-therapy

Rocket Pharmaceuticals shares rise after FDA clears its pivotal RP-A501 trial for Danon disease with adjusted dosing and update...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION